Health Minister Robbie Butler has acknowledged that cancer waiting times in Northern Ireland remain “not acceptable” despite highlighting a significant improvement in breast cancer waits, as the latest official statistics expose the scale of challenge facing the health service.
The Minister, appointed on 20 August 2026 following Mike Nesbitt’s resignation, pointed to a reduction in median breast cancer waiting times from 56 days in September 2025 to 38 days in June 2026. However, this selective improvement stands against a backdrop of continued failure to meet national cancer targets across most tumour types.
Breast cancer improvement masks broader struggles
The Department of Health’s latest figures show that while breast cancer waits have improved, the overall position for cancer patients remains poor. The 62-day target—requiring 95% of patients to begin treatment within 62 days of an urgent GP referral—continues to be missed across Northern Ireland.
According to the most recent validated data published in September 2026, only 29.5% of patients began treatment within 62 days in the quarter ending December 2025, far below the 95% target. The 31-day target, requiring 98% of patients to start treatment within 31 days of a decision to treat, was also missed, with 90.1% treated on time.
The Minister attributed the breast cancer improvement to several initiatives:
- £5 million invested through the Elective Care Framework
- Establishment of a regional Breast Operational Delivery Network
- Additional clinic capacity to address backlogs
Minister’s statement: “Relentless focus” required
Robbie Butler, who took office following a row over emergency surgery services at Causeway Hospital, struck a candid tone about the difficulties ahead.
“Behind every figure is a person waiting for answers and a family living with uncertainty. A suspected cancer diagnosis can be frightening, and I understand how distressing it is when people then face a long wait for assessment or treatment.
“Today’s figures show the scale of the challenge before us. Whilst there has been great progress made on tackling elective waiting times and innovations in cancer treatments are constantly improving, the overall waiting times position for cancer is not acceptable.”
The Minister added:
“There is no doubt that there is still much more to do. As a new Minister, I want to explore what opportunity exists to do more and drive further improvement more rapidly. This work needs consistent leadership and relentless focus.”
Elective Care Framework: The promised roadmap
Butler positioned the Elective Care Framework (ECF) as “the roadmap for tackling our cancer waits on a sustainable basis.” The ECF was originally published in June 2021 and updated in May 2024, with the Department stating it requires £80 million annually in recurrent funding when fully implemented, plus £135 million per year in non-recurrent funding over five years.
The Minister noted that Programme for Government funding has been targeted at reducing waits for cancer diagnostics and treatment, including investment in endoscopy, imaging, workforce and phlebotomy.
“In addition to this targeted investment, we are actively understanding, managing and improving whole cancer pathways through structured review, shared learning and strengthened accountability,”
Butler said.
Political context and unanswered questions
Butler’s statement referenced “political stability” as important for health service improvement—a comment that carries particular weight given the circumstances of his appointment. His predecessor Mike Nesbitt resigned on 19 August 2026 following public disagreement with UUP leader Jon Burrows over hospital reconfiguration plans, with Butler appointed the following day.
Several important questions emerge from the latest data and the Minister’s response:
- Why has breast cancer seen measurable improvement while other cancer types continue to miss targets by substantial margins?
- How does the £5 million breast cancer investment compare to overall cancer spending, and is this level of funding sufficient for system-wide improvement?
- What specific actions will be taken to address the 62-day and 31-day targets for non-breast cancers, given these remain far from achievement?
- With an Assembly election due in May 2027, how much meaningful change can be delivered in the remaining seven months of the current mandate?
Context: How Northern Ireland compares
Direct comparison between UK nations is complicated by differing measurement methods, but available data suggests Northern Ireland faces particular challenges. England’s 62-day target performance stood at 71.2% in July 2026—below its 85% target but higher than Northern Ireland’s 29.5%, according to Cancer Research UK analysis. Scotland met its 95% target for the 31-day standard in September 2025.
The Department has faced data quality issues, with revised 62-day figures published in September 2026 following the discovery of a calculation error in the ‘encompass’ electronic patient record system. This affected 9% of patients with suspended treatment starts, with previous calculations having understated waiting times.
What happens next
Butler’s statement commits to “relentless focus” but offers few specific new commitments beyond existing ECF plans. With the Minister in post for only six weeks and facing an election within seven months, the window for substantive reform is narrow.
The next quarterly cancer waiting times statistics, covering April-June 2026, will provide an early indication of whether the breast cancer improvement represents genuine momentum or an isolated advance. For the thousands of patients currently waiting for cancer assessment and treatment across Northern Ireland, the difference matters profoundly.